INTRODUCTION
Since the 1960s, bioactive secondary metabolites were isolated and structurally characterised from microorganisms which have adopted strategies to grow in extreme terrestrial environments (Lesley-Ann & David 2015) . Glaciozyma antarctica PI12 belongs to the family Kriegeriales (Di Menna 1960) and was isolated from a marine environment in Antarctica (Fell et al. 1969) . Recently, this psychrophilic yeast was reclassified from Leucosporidium antarcticum to Glaciozyma antarctica PI12 (Turchetti et al. 2011 ) and was also isolated from various locations in Antarctica (Connell et al. 2008; Donachie 1995) . Turkiewicz et al. (2005) reported that G. antarctica PI12 has optimum growth temperature of around 15°C and is able to tolerate higher temperatures up to 20°C (Morita 1975) .
This paper reports the isolation and elucidation of secondary metabolites from G. antarctica PI12 fermented at 12°C with complete nutrient (optimised growth conditions). A new dipeptide, (-)glaciantarcin (1) and three known compounds, cyclo(-Pro,Gly) (2) (Ishizu et al. 1991) , 1-(2-deoxypentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione (Setyowati et al. 2008 ) and vidarabine (Ara-A) (4) (Lagoja 2005) , were isolated from the ethyl acetate extract of G. antarctica PI12 and their structures were established by Nuclear Magnetic Resonance Spectroscopy and Mass Spectrometry techniques. The antioxidant properties and cytotoxicity activity of compounds 1-4 against two cancer cell lines, MCF-7 and PC-3 and the normal cell line HEK 293 are also included.
MATERIALS AND METHODS

GENERAL
Silica gel; Kieselgel 60 PF254 (art. no. 7749, Merck) and aluminum sheets 20 × 20 cm of the silica gel 60 F254 of 0.25 mm thickness (art. no. 5554, MERCK) were used for radial and thin layer chromatography, respectively. Structures of the pure compounds were determined based on the spectral data recorded on Shimadzu UV-260 spectrophotometer, optical rotation (Rudolph research analytical, Autopol VI), Jasco J-815 CD spectrometer, Frontier Perkin-Elmer FTIR/NIR spectrophotometer and Bruker NMR 700 MHz cryo-probe instrument that included 1-D and 2-D NMR. ESI-MS were recorded by using LCMSUltra performance liquid chromatography (UPLC), Brand WATER.
BIOLOGICAL MATERIAL AND CULTIVATION OF YEAST
The G. antarctica PI12 was originally isolated from Casey Research Station, in Antarctica. This yeast was identified based on its biochemical characteristics and the sequence of the internal transcribed spacer (ITS) as well as the LSU rRNA (Accession numbers JX89896955 and JX896956) by the National Collection of Yeast Cultures, Norwich, UK. The strain was cultured on Tryptic Soy Agar for 10 days at 4°C until a single colony was obtained (Hashim et al. 2014) . Firstly, 10 μL of the G. antarctica PI12 glycerol stock was sub-cultured on the YPD agar with 50 μg/mL of ampicillin and 50 μg/mL kanamycin at 12°C until a single colony was obtained. Secondly, a starter culture of G. antarctica PI12 was prepared by inoculating a single colony of G. antarctica PI12 from the agar plate into 10 mL of YPD medium (50 mL falcon tube) with 50 μg/mL of ampicillin and 50 μg/mL kanamycin. Then it was cultured at 12°C at 180 rpm until mid-log phase (OD600: 1.0 to 1.8) (5 days). Thirdly, a fixed amount (10 6 yeast cells/mL) of starter culture was inoculated into 50 mL of YPD medium (three units of 250 mL conical flask were used) with two antibiotics and then cultured at 12°C at 180 rpm until stationary phase on day 14 (Hashim et al. 2013 ).
EXTRACTION AND ISOLATION
The fermented culture was centrifuged at 10,000 rpm, 4°C, for 5 min. The supernatant was filtered to remove cell debris and extracted thrice with ethyl acetate, to be concentrated under reduce pressure evaporator. The EtOAc extract (200.7 mg) of G. antarctica PI12 was subjected to radial chromatography (RC) with 1 mm thickness silica gel on a round glass plate and eluted with mixtures of DCM and MeOH with increasing polarity (initially DCM/MeOH, 9.6 : 0.4). Eluents that showed the same profile on thin layer chromatography (TLC) chromatogram were combined to give three fractions (I-III). Purification of fraction I (1-4) (29.7 mg) was carried out by using RC with a silica gel plate of 0.5 mm thickness eluted with DCM and MeOH (9.2:0.8) in 5% polarity increment to yield compound 1 (4 mg). Purification of fraction II (5-7) (48.8 mg) was conducted by utilising another RC with silica gel plate of 0.5 mm thickness. Elution with DCM and MeOH (8.4:1.6) provided compound 2 (2 mg), compound 3 (1.5 mg) and compound 4 (7.5 mg).
CYTOTOXICITY ASSAY
Compounds 1-4 were subjected to anticancer screening by using breast adenocarcinoma cells (MCF-7) and human prostate cancer cells (PC-3). Toxicity assessment of the compounds was conducted by using human embryonic kidney normal cell line (HEK-293). All cell lines were grown in a suitable media and maintained in a humidified atmosphere of 95% air and 5% CO 2 at 37°C. For the assay, cells were detached, centrifuged and the viability of the cells was determined by Trypan blue dye exclusion technique. The cell suspension was diluted to give the optimal cell seeding density. Cytotoxic analysis of the cells was determined by using iCELLigence impedancebased, time-dependent cellular response profiles (TCRPs) system and further confirmed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The anticancer drug, doxorubicin was used as a positive control. C e l l v i a b i l i t y w a s a s s e s s e d b y u s i n g 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, which was based on the reduction of MTT by mitochondrial dehydrogenases of viable cells to a purple formazan product. Firstly, cells were plated at 2.5 × 10 4 cells/mL of density in 96-well plate. After an overnight growth, the cells were treated with Compounds 1-4, with concentrations ranging from 12.5 to 400 μM for 48 h. Next, the cells were incubated with 10 μL of 4 mg/ mL MTT dye at 37°C for 3 h. After the media was removed from the plate, 100 μL of DMSO was added, followed by absorbance measurement at 570 nm by using a microplate reader (Mosmann 1983) . ANTIOXIDANT (DPPH) The stock concentration of each compound was 1 mg/mL in MeOH. For bioassay, 50 μL of each sample was added to 150 μL of 0.3 mM solution of DPPH. The mixture was vigorously shaken and allowed to stand in a dark place for 30 min; the absorbance at 517 nm was determined by using a UV spectrophotometer and the scavenging activity percentage was calculated. A blank solution of MeOH was prepared. BHT (butylated hydroxy toluene) and BHA (butylated hydroxy anisole) were used as positive controls (Brand-Williams et al. 1995 
RESULTS AND DISCUSSION
A new compound, (-)-glaciantarcin (1) was isolated as white amorphous solid (Figure 1) . Two signals of methines at δ c 100.9 (C-6) and 142.0 (C-7) indicated the presence of an olefinic carbon, that is linked to a quaternary carbon C-5, while the other three shielded carbons (C-3, C-8, and C-9) showed the existence of an aliphatic amide in the molecule. The DBE value of C 7 H 11 N 3 O 2 is four, indicating that the alkaloid consists of three double bonds (one olefinic and two carbonyls) and one ring of diazepine derivative.
The structure of Compound 1 was confirmed by using 2D NMR, including HMBC and H 1 /H 1 COSY. The HMBC experiment showed that H-8 has correlations with carbonyl C-5 and methylene C-3, confirming the position of the 4-(1-aminoethyl) as a branch in this molecule (Figure 2 ).
Most probably Compound 1 was derived from the nonribosomal peptide synthetase (bimodular NRPS) pathway. The proposed mechanism was by using β-amino acid (3-amino-3-hydroxy propanoic acid) as the starter FIGURE 1. Compounds isolated from G. antarctica PI12 FIGURE 2. 2D Correlation NMR of (-)-glaciantarcin (1); HMBC (→), COSY (--) unit with glycine as extender (Figure 3 ). The utilisation of β-amino acid as a starter was well established in the microbial metabolites (Kudo et al. 2014) . These substrates were tethered to the thiolation domains of the NRPS and underwent condensation reaction. Next, subsequent cyclisation and dehydration took place for the formation of the seven-membered diazepine ring 13. Further modifications were needed for the production of Compound 1.
Further purification with radial chromatography afforded another dipeptide (Compound 2), and pyrimidine derivatives Compound 3 and Compound 4. All these compounds were known, and were isolated from microbial sources. Compounds 2-4 were identified: Compound 2 was cyclo(Pro-Gly), Compound 3 was 1-(2-deoxypentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione, and Compound 4 was vidarabine (Ara-A) by comparison of their NMR and MS data with the reported values in literature. This is the first report on Compounds 1-4 from G. antarctica PI12 (Figure 1) .
Compound 2 was reported to be first isolated from fungi Aspergillus fumigatus, with antimicrobial activities (Furtado et al. 2005) . The pyrimidine derivative Compound 3 was originally isolated from sponge, with in vitro cytotoxicity (HeLa, Raji and myolema cells) bioactivities (Setyowati et al. 2008) . Compound 4 was originally developed as a synthetic analogue from spongouridine, a compound isolated from the Caribbean sponge Tethya crypta (Tethylidae) with good antiviral activity (Bergmann et al. 1951) . However, Compound 4 was isolated from . Proposed Biosynthesis of (-)-glaciantarcin (1) sponge Haliclona sp., proving that this compound can also be synthesised by a biological system (Wang et al. 2009 ). All of the isolated Compounds (1-4) were assayed for cytotoxicity against human breast cancer (MCF-7) and human prostate cancer (PC-3) cell lines. Their toxicity towards normal cells was also tested by using a normal human embryonic kidney (HEK-293) cell line. At the highest concentration of 400 μM, all compounds showed the best activity on MCF-7, with Compound 1 (65%), Compound 2 (70%), Compound 3 (66%) and Compound 4 (58%) cell viability. A lower concentration of all compounds gave more than 70% cell viability. The DPPH radical scavenging activity of the compounds showed weak antioxidant activities at a fixed concentration of 100 μM; with Compounds 1-4 at 7.49%, 24.83%, 11.56%, and 4.15%, respectively.
CONCLUSION
The investigation on the chemical constituents from EtOAc extract of psychrophilic yeast Glaciozyma antarctica PI12 resulted in the isolation of a new compound namely (-)-glaciantarcin (1) and three known compounds which were cyclo(-Pro-Gly) (2), 1-(2-deoxypentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione (3) and vidarabine (Ara-A) (4). In cytotoxicity bioassay, at the concentration of 400 μM, all compounds showed the highest activity on MCF-7, with Compounds 1-4 at 65%, 70%, 66% and 58% cell viability, respectively. All compounds showed weak DPPH radical scavenging activity. This study shows that Glaciozyma antarctica mainly produces nitrogen-based compounds when grown in optimised conditions.
